{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:48Z","timestamp":1786120308323,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/bor.0b013e32834aa40b","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T19:53:22Z","timestamp":1317758002000},"page":"555-561","source":"Crossref","is-referenced-by-count":53,"title":["Contemporary management of Raynaud's phenomenon and digital ischaemic complications"],"prefix":"10.1097","volume":"23","author":[{"given":"Ariane L.","family":"Herrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210128","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/BOR.0b013e3282f13137","article-title":"Current drug therapy for scleroderma and secondary Raynauds phenomenon: evidence-based review.","volume":"19","author":"Henness","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"R2-8-20210128","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0002-9343(85)90402-4","article-title":"Nifedipine in the treatment of Raynauds phenomenon: evidence for inhibition of platelet activation.","volume":"78","author":"Malamet","year":"1985","journal-title":"Am J Med"},{"key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.amjmed.2003.11.022","article-title":"Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis.","volume":"116","author":"Allanore","year":"2004","journal-title":"Am J Med"},{"key":"R4-8-20210128","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","article-title":"Calcium-channel blockers for Raynauds phenomenon in systemic sclerosis.","volume":"44","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","article-title":"Calcium channel blockers for primary Raynauds phenomenon: a meta-analysis.","volume":"44","author":"Thompson","year":"2005","journal-title":"Rheumatology"},{"key":"R7-8-20210128","first-page":"1125","article-title":"Raynauds phenomenon (secondary).","volume":"9","author":"Herrick","year":"2008","journal-title":"Clinical evidence (BMJ Publishing Group Ltd)"},{"key":"R8-8-20210128","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynauds phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/art.22965","article-title":"Prevention of vascular damage in scleroderma and autoimmune Raynauds phenomenon.","volume":"56","author":"Gliddon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynauds phenomenon with the selective serotonin reuptake inhibitor fluoxetine.","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatol"},{"key":"R12-8-20210128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"key":"R14-8-20210128","first-page":"1830","article-title":"Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynauds phenomenon and systemic sclerosis: a randomized, open, single-center study.","volume":"35","author":"Kawald","year":"2008","journal-title":"J Rheumatol"},{"key":"R15-8-20210128","first-page":"269","article-title":"Adventitial stripping: a digit saving procedure in refractory Raynauds phenomenon.","volume":"25","author":"Yee","year":"1998","journal-title":"J Rheumatol"},{"key":"R16-8-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/micr.1013","article-title":"Surgery for ischemic pain and Raynauds phenomenon in scleroderma: a description of treatment protocol and evaluation of results.","volume":"21","author":"Tomaino","year":"2001","journal-title":"Microsurgery"},{"key":"R17-8-20210128","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jhsa.2009.05.003","article-title":"Long-term results of periarterial sympathectomy.","volume":"34","author":"Hartzell","year":"2009","journal-title":"J Hand Surg (American)"},{"key":"R18-8-20210128","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynauds phenomenon resistant to vasodilatory therapy.","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"key":"R19-8-20210128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archinte.166.2.231","article-title":"Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease.","volume":"166","author":"Caglayan","year":"2006","journal-title":"Arch Intern Med"},{"key":"R20-8-20210128","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3899\/jrheum.090270","article-title":"Randomised placebo-controlled crossover trial of tadalafil in Raynauds phenomenon secondary to systemic sclerosis.","volume":"36","author":"Schiopu","year":"2009","journal-title":"J Rheumatol"},{"key":"R21-8-20210128","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynauds phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatol"},{"key":"R22-8-20210128","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.30195","article-title":"Modified-release sildenafil reduces Raynauds phenomenon attack frequency in limited cutaneous systemic sclerosis.","volume":"63","author":"Herrick","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R23-8-20210128","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/ard.2009.116475","article-title":"Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.","volume":"69","author":"Brueckner","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R24-8-20210128","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/01.CIR.3.5.681","article-title":"The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynauds disease and Raynauds phenomenon: studies on blood flow and clinical manifestations.","volume":"3","author":"Kleckner","year":"1951","journal-title":"Circulation"},{"key":"R25-8-20210128","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","article-title":"Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynauds phenomenon.","volume":"34","author":"Teh","year":"1995","journal-title":"Br J Rheumatol"},{"key":"R26-8-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/rheumatology\/kep309","article-title":"A retrospective clinical analysis of pharmacological modalities used for symptomatic relief of Raynauds phenomenon in children treated in a UK paediatric rheumatology centre.","volume":"49","author":"Gargh","year":"2010","journal-title":"Rheumatol"},{"key":"R27-8-20210128","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/art.24351","article-title":"MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynauds phenomenon.","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R28-8-20210128","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0008-6363(96)00219-2","article-title":"Cardiopulmonary effects of endothelin-1 in man.","volume":"33","author":"Kiely","year":"1997","journal-title":"Cardiovasc Res"},{"key":"R29-8-20210128","first-page":"1268","article-title":"Localization of endothelin-1 and its binding sites in scleroderma skin.","volume":"21","author":"Vancheeswaran","year":"1994","journal-title":"J Rheumatol"},{"key":"R30-8-20210128","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.tips.2007.10.002","article-title":"Selective and mixed endothelin receptor antagonism in cardiovascular disease.","volume":"28","author":"Dhaun","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"R31-8-20210128","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"for the RAPIDS-1 Study GroupDigital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R32-8-20210128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"R33-8-20210128","first-page":"S239","article-title":"Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging (abstract).","volume":"62","author":"Bose","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R34-8-20210128","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/rheumatology\/kep413","article-title":"Effect of the dual endothelin receptor antagonist bosentan on Raynauds phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.","volume":"49","author":"Nguyen","year":"2010","journal-title":"Rheumatology"},{"key":"R35-8-20210128","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/art.21899","article-title":"Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis.","volume":"54","author":"Kuwana","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R36-8-20210128","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1136\/ard.2005.046870","article-title":"Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study.","volume":"65","author":"Furukawa","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R37-8-20210128","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/art.21723","article-title":"Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin.","volume":"54","author":"Louneva","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R38-8-20210128","first-page":"25","article-title":"Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents Autoimmun R","volume":"5","author":"Derk","year":"2006","journal-title":"ev"},{"key":"R39-8-20210128","first-page":"1801","article-title":"Statins: potentially useful in therapy of systemic sclerosis-related Raynauds phenomenon and digital ulcers.","volume":"35","author":"Abou-Raya","year":"2008","journal-title":"J Rheumatol"},{"key":"R40-8-20210128","first-page":"4","article-title":"The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis.","volume":"19","author":"Herrick","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"R41-8-20210128","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s10067-009-1251-7","article-title":"The treatment with N-acetylcysteine of Raynauds phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients.","volume":"28","author":"Rosato","year":"2009","journal-title":"Clin Rheumatol"},{"issue":"Suppl 54","key":"R42-8-20210128","first-page":"S51","article-title":"Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis.","volume":"27","author":"Fiori","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"R43-8-20210128","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.prs.0000244860.00674.57","article-title":"Management of vasospastic disorders with botulinum toxin A.","volume":"119","author":"Van Beek","year":"2007","journal-title":"Plast Reconstr Surg"},{"key":"R44-8-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/PRS.0b013e3181a80576","article-title":"Botox therapy for ischemic digits.","volume":"124","author":"Neumeister","year":"2009","journal-title":"Plast Reconstr Surg"},{"key":"R45-8-20210128","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/BOR.0b013e3282eeb3a4","article-title":"Platelet contributions to the pathogenesis of systemic sclerosis.","volume":"19","author":"Postlethwaite","year":"2007","journal-title":"Curr Opin Rhematol"},{"key":"R46-8-20210128","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.1780271009","article-title":"Trial of platelet-inhibiting drug in scleroderma: double-blind study with dipyridamole and aspirin.","volume":"27","author":"Beckett","year":"1984","journal-title":"Arthritis Rheum"},{"key":"R47-8-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.rdc.2007.12.005","article-title":"Regulation of vascular reactivity in scleroderma: new insights into Raynauds phenomenon.","volume":"34","author":"Flavahan","year":"2008","journal-title":"Rheum Dis Clin N Am"},{"key":"R48-8-20210128","first-page":"321","article-title":"Pulmonary hypertension: beyond vasodilator therapy.","volume":"338","author":"Fishman","year":"1998","journal-title":"N Engl J Med"},{"key":"R49-8-20210128","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1053\/hj.1998.v135.86971","article-title":"Vascular remodeling: the role of angiotensin-converting enzyme inhibitors.","volume":"135","author":"Chrysant","year":"1998","journal-title":"Am Heart J"},{"key":"R50-8-20210128","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1525-1373.1999.d01-88.x","article-title":"Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling.","volume":"221","author":"Kirchengast","year":"1999","journal-title":"PSEBM"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e32834aa40b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:27:30Z","timestamp":1786048050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-201111000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e32834aa40b","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}